Cannabis Law Report

DECEMBER 23, 2021

billion by 2025. The market sizing section provides forecasts on the estimated sales of the three most lucrative cannabinoid pharmaceuticals – from 2021-2025 – including Epidiolex, Sativex and Dronabinol. Global surveys of cannabis users indicate that around 40% of users have some medical component to their usage.

Pharmaceutical 96

Pharmaceutical Clinical Trials Research and Development Cannabinoids 96

Cannabis Law Report

JULY 15, 2022

“It’s very important from our perspective to ensure that the Australian patient gets medicine first. The first medicinal cannabis ‘mother’ plants are expected to be imported from Israel within a month, with manufacturing scheduled to begin within the first half of this year, to supply 5,000 Australian patients.

Medicine 52

Medicine Patients Media Supply Chain 52

Cannabis Law Report

OCTOBER 17, 2019

Plants with higher THC levels are typically bred and consumed for medical or adult recreational purposes, either in dried form for smoking or with the THC content extracted and infused into foods, beverages, topical ointments, candles, and other products. billion in 2025, according to Grandview Research.

Law 40

Law Seed-To-Sale Hemp Recreational 40

Cannabis Law Report

MAY 19, 2019

Cannabis plant or its resin or extract with THC content lower than 1% is considered as CBD (medical) cannabis and not psychoactive. billion dollars by 2025. Ingesting cannabis helps lower the pressure in the eyeball, giving patients at least temporary relief. Underlining supplied for emphasis). Health Benefits of Cannabis.

Legalization 45

Legalization Seed-To-Sale Marijuana Decriminalization 45